Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study

被引：0

作者：

Kuemmel, Sherko ^{[1
,2
]}

Schmid, Peter ^{[3
]}

Harbeck, Nadia ^{[4
]}

Takahashi, Masato ^{[5
]}

Untch, Michael ^{[6
]}

Boileau, Jean-Francois ^{[7
]}

Cortes, Javier ^{[8
,9
]}

McArthur, Heather ^{[10
]}

Dent, Rebecca ^{[11
]}

O'Shaughnessy, Joyce ^{[12
]}

Pusztai, Lajos ^{[13
]}

Foukakis, Theodoros ^{[14
,15
]}

Park, Yeon Hee ^{[16
]}

Hui, Rina ^{[17
,18
]}

Cardoso, Fatima ^{[19
]}

Denkert, Carsten ^{[20
,21
]}

Zhu, Yalin ^{[22
]}

Pan, Wilbur ^{[22
]}

Karantza, Vassiliki ^{[22
]}

Fasching, Peter A. ^{[23
]}

机构：

[1] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[2] Charite Univ Med Berlin, Dept Gynecol Breast Ctr, Berlin, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] LMU Univ Hosp, Breast Ctr, Munich, Germany

[5] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[6] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany

[7] McGill Univ, Jewish Gen Hosp Segal Canc Ctr, Montreal, PQ, Canada

[8] Quiron Grp, Int Breast Canc Ctr, Pangaea Oncol, Barcelona, Spain

[9] Univ Europea Madrid, Madrid, Spain

[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA

[11] Duke Natl Univ Singapore Med Sch, Natl Canc Ctr Singapore, Singapore, Singapore

[12] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA

[13] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[14] Karolinska Inst, Solna, Sweden

[15] Karolinska Univ Hosp, Breast Canc Ctr, Karolinska Comprehens Canc Ctr, Solna, Sweden

[16] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[17] Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia

[18] Univ Sydney, Sydney, NSW, Australia

[19] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[20] Philipps Univ Marburg, Inst Pathol, Marburg, Germany

[21] Univ Hosp Marburg, Marburg, Germany

[22] Merck & Co Inc, Rahway, NJ USA

[23] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany

来源：

ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1462344

引用

页码：S295 / S296

页数：2

共 50 条

[21] Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
Pusztai, Lajos
Denkert, Carsten
O'Shaughnessy, Joyce
Cortes, Javier
Dent, Rebecca Alexandra
McArthur, Heather L.
Kuemmel, Sherko
Bergh, Jonas C. S.
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Zhu, Yalin
Pan, Wilbur
Tryfonidis, Konstantinos
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756
Cardoso, Fatima
O'Shaughnessy, Joyce
McArthur, Heather
Schmid, Peter
Cortes, Javier
Harheck, Nadia
Telli, Melinda L.
Cescon, David W.
Fasching, Peter A.
Shao, Zhimin
Loirat, Delphine
Park, Yeon Hee
Gonzalez Fernandez, Manuel
Rubovszky, Gabor
Im, Seock-Ah
Hui, Rina
Takano, Toshimi
Andre, Fabrice
Yasojima, Hiroyuki
Liu, Zhenzhen
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S4 - S5
[23] Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Dent, Rebecca
Cortes, Javier
Pusztai, Lajos
McArthur, Heather
Kuemmel, Sherko
Bergh, Jonas
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Haiderali, Amin
Jia, Liyi
Nguyen, Allison Martin
Pan, Wilbur
O'Shaughnessy, Joyce
Schmid, Peter
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (10): : 1654 - 1663
[24] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
Cardoso, Fatima
O'Shaughnessy, Joyce
McArthur, Heather
Schmid, Peter
Cortes, Javier
Harbeck, Nadia
Telli, Melinda
Cescon, David
Fasching, Peter A.
Shao, Zhimin
Loirat, Delphine
Park, Yeon Hee
Fernandez, Manuel Gonzalez
Rubovszky, Gabor
Im, Seock-Ah
Hui, Rina
Takano, Toshimi
Andre, Fabrice
Yasojima, Hiroyuki
Liu, Zhenzhen
Ding, Yu
Jia, Liyi
Karantza, Vassiliki
Tryfonidis, Konstantinos
Bardia, Aditya
CANCER RESEARCH, 2024, 84 (09)
[25] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
Cortes, J.
Cescon, D. W.
Rugo, H. S.
Im, S-A.
Yusof, M. Md
Gallardo, C.
Lipatov, O.
Barrios, C. H.
Perez-Garcia, J.
Iwata, H.
Masuda, N.
Otero, M. Torregroza
Gokmen, E.
Loi, S.
Guo, Z.
Zhou, X.
Karantza, V.
Pan, W.
Schmid, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
[26] Neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for earlystage high-risk ER+/HER2-breast cancer: Results from the phase 3 KEYNOTE-756 study
Cardoso, F.
O'Shaughnessy, J.
McArthur, H.
Schmid, P.
Cortes, J.
Harbeck, N.
Telli, M. L.
Cescon, D. W.
Fasching, P.
Shao, Z.
Loirat, D.
Park, Y. H.
Gonzalez Fernandez, M.
Rubovszky, G.
Im, S. A.
Hui, R.
Takano, T.
Andre, F.
Yasojima, H.
Liu, Z.
Ding, Y.
Jia, L.
Karantza, V.
Tryfonidis, K.
Bardia, A.
EUROPEAN JOURNAL OF CANCER, 2024, 200 : 10 - 11
[27] KEYNOTE-355 Asian subset: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for triple-negative breast cancer
Takano, Toshimi
Cortes, Javier
Cescon, David W.
Im, Seock-Ah
Yusof, Mastura Md
Iwata, Hiroji
Masuda, Norikazu
Huang, Chiun-Sheng
Chung, Chi-Feng
Tsugawa, Koichiro
Park, Yeon Hee
Matsumoto, Koji
Inoue, Kenichi
Kwong, Ava
Loi, Sherene
Fu, Wei
Pan, Wilbur
Karantza, Valia
Rugo, Hope S.
Schmid, Peter
ANNALS OF ONCOLOGY, 2022, 33 : S465 - S465
[28] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
[29] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[30] KEYNOTE-585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David H.
Hyung, Woo Jin
Strong, Vivian E.
Goetze, Thorsten Oliver
Yoshikawa, Takaki
Tang, Laura H.
Hwang, Peggy May Tan
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →